|
| 38049664 | The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance. | Nat Genet | 2024 |
| 37398210 | FET fusion oncoproteins disrupt physiologic DNA repair networks and induce ATR synthetic lethality in cancer. | Res Sq | 2023 |
| 37961102 | The essential chaperone DNAJC17 activates HSP70 to coordinate RNA splicing and G2-M progression. | bioRxiv | 2023 |
| 38065059 | Unlocking the EGFR-mediated epitranscriptome: A pathway to novel therapies. | Mol Cell | 2023 |
| 37280434 | Author Correction: 3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinib. | Commun Biol | 2023 |
| 37205599 | FET fusion oncoproteins disrupt physiologic DNA repair networks in cancer. | bioRxiv | 2023 |
| 37370745 | Long Non-Coding RNAs as Emerging Targets in Lung Cancer. | Cancers (Basel) | 2023 |
| 35166243 | Remodeling of the tumor/tumor microenvironment ecosystem during KRAS G12C inhibitor clinical resistance in lung cancer. | J Clin Invest | 2022 |
| 35353542 | Small-molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cells. | Sci Transl Med | 2022 |
| 35523183 | Lineage tracing reveals the phylodynamics, plasticity, and paths of tumor evolution. | Cell | 2022 |
| 36545322 | Phase 1 Study of Ceritinib Combined With Trametinib in Patients With Advanced ALK- or ROS1-Positive NSCLC. | JTO Clin Res Rep | 2022 |
| 36137002 | Primary and metastatic tumors exhibit systems-level differences in dependence on mitochondrial respiratory function. | PLoS Biol | 2022 |
| 36358671 | Quantitative Framework for Bench-to-Bedside Cancer Research. | Cancers (Basel) | 2022 |
| 35895872 | AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer. | Cancer Discov | 2022 |
| 36282590 | GATOR2-dependent mTORC1 activity is a therapeutic vulnerability in FOXO1 fusion-positive rhabdomyosarcoma. | JCI Insight | 2022 |
| 35101231 | Inhibition of SHP2 as an approach to block RAS-driven cancers. | Adv Cancer Res | 2022 |
| 35060299 | Digital multiplexed analysis of circular RNAs in FFPE and fresh non-small cell lung cancer specimens. | Mol Oncol | 2022 |
| 34872888 | Evolution of metastasis: new tools and insights. | Trends Cancer | 2022 |
| 35195258 | Understanding Drug Sensitivity and Tackling Resistance in Cancer. | Cancer Res | 2022 |
| 33479121 | Single-cell lineages reveal the rates, routes, and drivers of metastasis in cancer xenografts. | Science | 2021 |
| 33848463 | Kinase-mediated RAS signaling via membraneless cytoplasmic protein granules. | Cell | 2021 |
| 34866626 | Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids. | J Vis Exp | 2021 |
| 34408519 | Targeting AXL in NSCLC. | Lung Cancer (Auckl) | 2021 |
| 34446021 | DDX56 modulates post-transcriptional Wnt signaling through miRNAs and is associated with early recurrence in squamous cell lung carcinoma. | Mol Cancer | 2021 |
| 34246791 | Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. | J Thorac Oncol | 2021 |
| 34348154 | Exocyst protein subnetworks integrate Hippo and mTOR signaling to promote virus detection and cancer. | Cell Rep | 2021 |
| 34171262 | Stepwise evolution of therapy resistance in AML. | Cancer Cell | 2021 |
| 33418513 | Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment. | Curr Opin Chem Biol | 2021 |
| 31548343 | Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer. | Clin Cancer Res | 2020 |
| 32055785 | Overcoming the challenges of cancer drug resistance through bacterial-mediated therapy. | Chronic Dis Transl Med | 2020 |
| 32018052 | AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells. | J Thorac Oncol | 2020 |
| 31678994 | Betacellulin drives therapy resistance in glioblastoma. | Neuro Oncol | 2020 |
| 33214553 | Functional screening identifies aryl hydrocarbon receptor as suppressor of lung cancer metastasis. | Oncogenesis | 2020 |
| 32822576 | Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing. | Cell | 2020 |
| 32905814 | Long non-coding RNA ESCCAL-1 promotes esophageal squamous cell carcinoma by down regulating the negative regulator of APOBEC3G. | Cancer Lett | 2020 |
| 32699215 | Multi-faceted epigenetic dysregulation of gene expression promotes esophageal squamous cell carcinoma. | Nat Commun | 2020 |
| 32642197 | EGFR targeted therapy resistance: current status, challenges, and future outlook. | J Thorac Dis | 2020 |
| 32540409 | Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations. | J Thorac Oncol | 2020 |
| 30686761 | Principles of Resistance to Targeted Cancer Therapy: Lessons from Basic and Translational Cancer Biology. | Trends Mol Med | 2019 |
| 31533235 | <i>BRAF</i> Mutations Classes I, II, and III in NSCLC Patients Included in the SLLIP Trial: The Need for a New Pre-Clinical Treatment Rationale. | Cancers (Basel) | 2019 |
| 31329165 | CIC-DUX4 oncoprotein drives sarcoma metastasis and tumorigenesis via distinct regulatory programs. | J Clin Invest | 2019 |
| 31426419 | Targeting Oncogenic BRAF: Past, Present, and Future. | Cancers (Basel) | 2019 |
| 30898918 | Dampening oncogenic RAS signaling. | Science | 2019 |
| 30898264 | Polytherapy and Targeted Cancer Drug Resistance. | Trends Cancer | 2019 |
| 30806814 | Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer. | Curr Oncol Rep | 2019 |
| 30992280 | Engineering Multidimensional Evolutionary Forces to Combat Cancer. | Cancer Discov | 2019 |
| 30683736 | Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for <i>PIK3CA</i>-altered head and neck cancer. | J Exp Med | 2019 |
| 30553716 | Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation. | Clin Lung Cancer | 2019 |
| 30478424 | Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer. | Nat Med | 2019 |
| 30565127 | Immunohistochemistry to Study YAP in Human Tissue Samples. | Methods Mol Biol | 2019 |